AllSci News
Oruka Therapeutics' ORKA-001 achieves 63.5% complete skin clearance in plaque psoriasis trial
Oruka Therapeutics reported Week 16 interim results from the EVERLAST-A Phase 2a trial of ORKA-001, a half-life extended IL-23p19 monoclonal antibody, in...
MSIDS Research Foundation and Hudson Valley Healing Arts Center report Alzheimer's biomarker normalization with dapsone therapy
MSIDS Research Foundation reports Alzheimer's biomarker normalization in chronic Lyme disease patient treated with dapsone combination therapy in Journal of...
Revolution Med starts patent spat over Erasca’s pan-RAS molecular glue ERAS-0015
Erasca, Inc. (USA) announced on April 27, 2026, via a US Securities and Exchange Commission Form 8-K filing, that Revolution Medicines, Inc.…
Sanofi's Q1'26 Earnings Call Highlights: Lunsekimig a new respiratory priority, amlitelimab safety profile defended
Sanofi signaled a strategic pivot toward lunsekimig as its next respiratory franchise asset while defending amlitelimab's path to regulatory submission...
Compass Therapeutics' tovecimig meets progression-free survival endpoint in Phase II/III biliary tract cancer trial
Compass Therapeutics (Nasdaq: CMPX) reported that tovecimig, its DLL4/VEGF-A bispecific antibody, met the key secondary endpoint of progression-free...
Novartis withdraws EMA application to expand Pluvicto into earlier prostate cancer setting
Novartis Withdraws EMA Application to Expand Pluvicto into Earlier Prostate Cancer Setting
Alltrna puts engineered tRNA therapeutic into first-in-human study
Alltrna, a Cambridge, Massachusetts-based Flagship Pioneering company, has received approval from Australia's Therapeutic Goods Administration to initiate a...
J&J’s anti-FcRn mAb Imaavy takes FDA Priority Review for wAIHA
Johnson & Johnson (NYSE: JNJ) announced receipt of US FDA Priority Review for the supplemental Biologics License Application (sBLA) for Imaavy (nipocalimab-aahu),…
Veradermics' oral minoxidil meets endpoints in Phase II/III male pattern hair loss trial
Veradermics (NYSE: MANE) reported that its extended-release oral minoxidil tablet, VDPHL01, met all primary and key secondary endpoints in a Phase II/III...
Terns’ BCR::ABL1 inhibitor earns FDA Breakthrough Therapy status for CML
Terns Pharmaceuticals (Nasdaq: TERN), headquartered in Foster City, California, announced that the US FDA granted Breakthrough Therapy Designation (BTD) to TERN-701, an…
Jazz Pharma’s bispecific antibody zanidatamab receives FDA Priority Review for HER2+ gastric cancer
Jazz Pharmaceuticals plc (Nasdaq: JAZZ), headquartered in Dublin, announced that the US FDA has accepted for filing with Priority Review a supplemental…
Eli Lilly acquires Ajax Therapeutics for USD 2.3b targeting myeloproliferative neoplasm treatments
Eli Lilly (NYSE: LLY) has agreed to acquire US-based Ajax Therapeutics, a private New York-incorporated biopharmaceutical company, for up to USD 2.3 billion...
Intellia starts FDA submission for in vivo Crispr therapy lonvo-z as one-time angioedema treatment
Intellia Therapeutics has initiated a rolling submission of a Biologics License Application (BLA) to the US FDA for Lonvoguran ziclumeran (lonvoguran...
CHMP gives nod for Arrowhead’s Redemplo in familial chylomicronemia syndrome
Arrowhead Pharmaceuticals has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommending authorization…
FDA points way forward for Compass Pathways' psilocybin in treatment-resistant depression
Compass Pathways has submitted a rolling New Drug Application (NDA) to the US FDA for COMP360 (synthetic psilocybin), seeking approval in patients with...
The AllSci Brief
Free, systematic R&D and deal news. Daily.